Outcome of Hemoperfusion in Severe COVID-19 Pneumonia
Keywords:
Hemoperfusion, COVID-19, Pneumonia, Cytokine stormAbstract
Background: Respiratory tract infection COVID-19 endemic is a major public health problem. Critical ill patients need ventilator support and have high mortality rate. The clinical severity associates with immune hyperresponsiveness (cytokine storm). Clinical improvement by hemoperfusion therapy which decreased cytokines level were reported but few data was acquired. Objective: This study aimed to reveal the outcome of hemoperfusion theryapy in severe COVID-19 pneumonia. Methods: We conducted retrospective study in severe COVID-19pneumonia patients who were treated by hemoperfusion at Nopparat Rajathanee Hospital between June 15th, 2021 and July 15th , 2021. Clinical and laboratory data were obtained by chart review. Results: There were 7 severe COVID-19 pneumonia patients treated by hemoperfusion; 2 were males and 5 were females, aged 40-64 years. Of these patients, 6 need ventilators and another needed only high flow nasal cannula. 2 days after hemoperfusion, 5 patients had respiratory conditions improvement (71.5%) and needed lower oxygen concentration delivery. 3 of these were dead (3/5, 60%) from nosocomial pneumonia and recurrent acute MI. 2 patients which had no clinical improvement after hemoperfusion died within 3 days. Conclusions: hemoperfusion seems to have clinical improvement of respiratory system but mortality rate is still high from other complication. So, cost-effectiveness of hemoperfusion needs further studies.
References
Wu Z, McGoogan JM. Characteristics of and important lessons from the Coronavirus Disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the chinese center for disease control and prevention. JAMA 2020;323(13):1239-42.
Biswas M, Rahaman S, Biswas TK, Haque Z, Ibrahim BJI. Association of sex, age, and comorbidities with mortality in COVID-19 patients: a systematic review and meta-analysis. Intervirology 2020;9:1-12.
Bonanad C, García-Blas S, Tarazona-Santabalbina F, Sanchis J, Bertomeu-González V, Fácila L, et al. The effect of age on mortality in patients with COVID-19: a meta-analysis with 611,583 subjects. J Am Med Dir Assoc 2020;21(7):915-8.
Parasher A. COVID-19: Current understanding of its pathophysiology, clinical presentation and treatment. Postgrad Med J 2021;97(1147):312-20.
Sterne JA, Murthy S, Diaz JV, Slutsky AS, Villar J, Angus DC, et al. Association between administration of systemic corticosteroids and mortality among critically ill patients with COVID-19: a meta-analysis. JAMA 2020;324(13):1330-41.
Ivashchenko AA, Dmitriev KA, Vostokova NV, Azarova VN, Blinow AA, Egorova AN, et al. AVIFAVIR for treatment of patients with moderate COVID-19: interim results of a phase II/III multicenter randomized clinical trial. medrxiv 2020;1-7.
Manabe T, Kambayashi D, Akatsu H, Kudo KJBid. Favipiravir for the treatment of patients with COVID-19: a systematic review and meta-analysis. BMC Infect Dis 2021;21(1):1-13.
Siemieniuk RA, Bartoszko JJ, Ge L, Zeraatkar D, Izcovich A, Kum E, et al. Drug treatments for covid-19: living systematic review and network meta-analysis. BMJ 2020; 370:m2980.
Ghosn L, Chaimani A, Evrenoglou T, Davidson M, Graña C, Schmucker C, et al. Interleukin‐6 blocking agents for treating COVID‐19: a living systematic review. Cochrane Database Syst Rev 2021;3(3):CD013881.
Rosas IO, Bräu N, Waters M, Go RC, Hunter BD, Bhagani S, et al. Tocilizumab in hospitalized patients with severe Covid-19 pneumonia. N Engl J Med 2021;384(16):1503-16.
Rampino T, Gregorini M, Perotti L, Ferrari F, Pattonieri EF, Grignano MA, et al. Hemoperfusion with cytoSorb as adjuvant therapy in critically Ill patients with SARS-CoV2 pneumonia. Blood Purif 2021;50(4-5):566-71.
Shadvar K, Tagizadiyeh A, Gamari AA, Soleimanpour H, Mahmoodpoor A. Hemoperfusion as a potential treatment for critically Ill COVID-19 Patients with cytokine storm. Blood Purif 2021;50(3):405-7.
Rifkin BS, Stewart IJ. Seraph-100 Hemoperfusion in SARS-CoV-2-infected patients early in critical illness: a case series. Blood Purif 2022;51(4):317-20.
Sandoval D, Rama I, Quero M, Hueso M, Gómez F, Cruzado JM. Treatment for severe COVID-19 with a biomimetic sorbent haemoperfusion device in patients on haemodialysis. Clin Kidney J 2021;14(5):1475-7.
Safari S, Salimi A, Zali A, Jahangirifard A, Bastanhagh E, Aminnejad R, et al. Extracorporeal hemoperfusion as a potential therapeutic option for severe COVID-19 patients; a narrative review. Arch Acad Emerg Med 2020;8(1):e67.
Zhou Q, Gao Y, Wang X, Liu R, Du P, Wang X, et al. Nosocomial infections among patients with COVID-19, SARS and MERS: a rapid review and meta-analysis. Ann Transl Med 2020;8(10):629.
Bardi T, Pintado V, Gomez-Rojo M, Escudero-Sanchez R, Lopez AA, Diez-Remesal Y, et al. Nosocomial infections associated to COVID-19 in the intensive care unit: clinical characteristics and outcome. Eur J Clin Microbiol Infect Dis 2021;40(3):495-502.
Yang J-W, Fan L-C, Miao X-Y, Mao B, Li M-H, Lu H-W, et al. Corticosteroids for the treatment of human infection with influenza virus: a systematic review and meta-analysis. Clin Microbiol Infect 2015;21(10):956-63.
RECOVERY Collaborative Group; Horby P, Lim WS, Emberson JR, Mafham M, Bell JL, Linsell L, et al. Dexamethasone in hospitalized patients with Covid-19. N Engl J Med 2021;384(8):693-704.
Edalatifard M, Akhtari M, Salehi M, Naderi Z, Jamshidi A, Mostafaei S, et al. Intravenous methylprednisolone pulse as a treatment for hospitalised severe COVID-19 patients: results from a randomised controlled clinical trial. Eur Respir J 2020;56(6):2002808.
Wang L. C-reactive protein levels in the early stage of COVID-19. Med Mal Infect 2020;50(4):332-4.
Chen W, Zheng KI, Liu S, Yan Z, Xu C, Qiao ZJAocm, et al. Plasma CRP level is positively associated with the severity of COVID-19. Ann Clin Microbiol Antimicrob 2020;19(1):18.
Shang W, Dong J, Ren Y, Tian M, Li W, Hu J, et al. The value of clinical parameters in predicting the severity of COVID‐19. J Med Virol 2020;92(10):2188-92.
Smilowitz NR, Kunichoff D, Garshick M, Shah B, Pillinger M, Hochman JS, et al. C-reactive protein and clinical outcomes in patients with COVID-19. Eur Heart J 2021;42(23):2270-9.
Peerapornratana S, Sirivongrangson P, Tungsanga S, Tiankanon K, Kulvichit W, Putcharoen O, et al. Endotoxin adsorbent therapy in severe COVID-19 pneumonia. Blood Purif 2021:1-8.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Department of Medical Services, Ministry of Public Health
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
บทความที่ได้รับการตีพิมพ์เป็นลิขสิทธิ์ของกรมการแพทย์ กระทรวงสาธารณสุข
ข้อความและข้อคิดเห็นต่างๆ เป็นของผู้เขียนบทความ ไม่ใช่ความเห็นของกองบรรณาธิการหรือของวารสารกรมการแพทย์
